专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

US20080171083A1 Pharmaceutical Compositions Comprising an Amphiphilic Starch 审中-公开
标题翻译：包含两亲性淀粉的药物组合物
公开(公告)号：US20080171083A1
公开(公告)日：2008-07-17
申请号：US11578271
申请日：2005-04-14
申请人： John Staniforth , Naresh Talwar
发明人： John Staniforth , Naresh Talwar
IPC分类号： A61K9/64 , A61K9/20
CPC分类号： A61K9/2059 , A61K9/2013
摘要： The present invention relates to controlled or sustained release solid pharmaceutical compositions, to pharmaceutical excipients for use in the manufacture of such compositions and to methods of producing such compositions and excipients. The controlled or sustained release excipients include a release controlling excipient comprising an amphiphilic starch.
摘要翻译：本发明涉及用于制备这种组合物的药用赋形剂的控释或持续释放的固体药物组合物以及制备这种组合物和赋形剂的方法。受控或持续释放的赋形剂包括包含两亲性淀粉的释放控制赋形剂。

3. 发明申请

US20060099245A1 Hydrodynamically balancing oral drug delivery system with biphasic release 审中-公开
标题翻译：流体动力平衡口服药物输送系统与双相释放
公开(公告)号：US20060099245A1
公开(公告)日：2006-05-11
申请号：US10514674
申请日：2002-05-21
申请人： Manoj Kumar , Naresh Talwar , Rajeev Raghuvanshi , Ashok Rampal
发明人： Manoj Kumar , Naresh Talwar , Rajeev Raghuvanshi , Ashok Rampal
IPC分类号： A61K9/48 , A61K9/64 , A61K9/22 , A61K31/403
CPC分类号： A61K9/0065 , A61K9/2866 , A61K9/4891
摘要： The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. The pharmaceutical composi-tion, either in the form of pellets (multiparticulate or single unit dosage form), beads, granules, capsules or tablets, is retained in the stomach while selectively delivering the drug(s) at gastrointestinal levels and upper parts of the small intestine over an extended period of time. The release of the drug from the said pharmaceutical composition is characterized by a biphasic release profile of the drug substance, which exhibits both immediate and controlled release characteristics.
摘要翻译：本发明涉及具有双相释放特征的口服药物递送系统，其包含多孔基质，其包含至少一种药物物质，糖，缓释聚合物，气体产生组分和任选的药物可接受的辅助成分，其中药物组合物还包含所述药物的涂层。以颗粒形式（多颗粒或单一单位剂型），珠粒，颗粒，胶囊或片剂的药物组合物保留在胃中，同时选择性地将药物在胃肠水平和小肠在较长时间内。药物从所述药物组合物的释放的特征在于药物物质的双相释放曲线，其表现出立即和控制释放特征。

4. 发明申请

US20050089572A1 Controlled release drug delivery system of pravastatin 审中-公开
标题翻译：普伐他汀的控释药物递送系统
公开(公告)号：US20050089572A1
公开(公告)日：2005-04-28
申请号：US10507513
申请日：2002-03-22
申请人： Manoj Kumar , Naresh Talwar , Rajeev Raghuvanshi , Ashok Rampal
发明人： Manoj Kumar , Naresh Talwar , Rajeev Raghuvanshi , Ashok Rampal
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28 , A61K9/54 , A61K31/22 , A61K31/225
CPC分类号： A61K9/2886 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K31/22
摘要： The present invention relates to an oral drug delivery system comprising pravastatin or its pharmaceutically acceptable salts such that the system provides enhanced stability in the acidic environment of the stomach and exhibits controlled release of the drug.
摘要翻译：本发明涉及包含普伐他汀或其药学上可接受的盐的口服药物递送系统，使得该系统在胃的酸性环境中提供增强的稳定性并显示出药物的受控释放。

5. 发明申请

US20090142398A1 NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A DISINTEGRATION MATRIX 审中-公开
标题翻译：包含消毒矩阵的新型药物组合物
公开(公告)号：US20090142398A1
公开(公告)日：2009-06-04
申请号：US12273937
申请日：2008-11-19
申请人： Mathew Philip , Naresh Talwar , Rasik Patel , Vinayak Pathak
发明人： Mathew Philip , Naresh Talwar , Rasik Patel , Vinayak Pathak
IPC分类号： A61K9/10 , A61K31/4184
CPC分类号： A61K9/2077 , A61K31/4184
摘要： The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active substance of 1:1 to 10:1, a water-insoluble pharmaceutically acceptable diluent, optionally, if desired or necessary at least one pharmaceutically acceptable excipients and/or pharmaceutically acceptable adjuvants, and optionally a pharmaceutically acceptable surfactant or emulsifier. The present invention also provides a process to make such.
摘要翻译：本发明涉及一种稳定的药物组合物，其包含分散在药学上可接受的崩解基质中的具有差的水溶性的药物活性物质，所述崩解基质包含至少一种药学上可接受的崩解剂，以碱性试剂的摩尔比提供的药学上可接受的碱性试剂至1：1至10：1的活性物质，任选地，如果需要或必需的至少一种药学上可接受的赋形剂和/或药学上可接受的佐剂，以及任选的药学上可接受的表面活性剂或乳化剂的水不溶性药学上可接受的稀释剂。本发明还提供了制造这样的方法。

6. 发明授权

US06960356B1 Orally administered drug delivery system providing temporal and spatial control 失效
标题翻译：口服给药系统提供时间和空间控制
公开(公告)号：US06960356B1
公开(公告)日：2005-11-01
申请号：US09347315
申请日：1999-07-02
申请人： Naresh Talwar , Himadri Sen , John N. Staniforth
发明人： Naresh Talwar , Himadri Sen , John N. Staniforth
IPC分类号： A61K9/00 , A61K9/22 , A61K9/26 , A61K9/28 , A61K9/46 , A61K9/52 , A61K31/496
CPC分类号： A61K9/0065 , A61K31/496
摘要： A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% profloxacin base, 0.34% sodium alginate, 1.103% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical xcipients, the formulation being in the form of a coated or uncoated tablet or capsule.
摘要翻译：片剂或胶囊形式的药物组合物提供药物递送到患者的时间和空间控制的组合以获得有效的治疗结果。药物组合物包含药物，气体发生组分，溶胀剂，粘稠剂和任选的凝胶形成聚合物。溶胀剂属于称为超级崩解剂的一类化合物（例如交联聚乙烯吡咯烷酮或羧甲基纤维素钠）。最初的粘稠溶剂和凝胶形成聚合物之后形成一种水合凝胶基质，其夹带气体，导致片剂或胶囊保留在胃或小肠上部（空间对照）中。同时，水合凝胶基质为药物产生曲折的扩散途径，导致药物的持续释放（时间控制）。优选的每日一次环丙沙星制剂包含69.9％的表氟沙星碱，0.34％的藻酸钠，1.103％的黄原胶，13.7％的碳酸氢钠，12.1％的交联的聚乙烯吡咯烷酮，以及任选的其它药物xcipients，该制剂是涂层或未包衣的片剂或胶囊。

7. 发明申请

US20100204292A1 Pharmaceutical compositions comprising intra-and extra-granular fractions 审中-公开
$Pharmaceutical compositions comprising intra-and extra-granular fractions$
标题翻译：包含颗粒内和颗粒外部分的药物组合物
公开(公告)号：US20100204292A1
公开(公告)日：2010-08-12
申请号：US12311700
申请日：2007-08-17
申请人： Jack Aurora , Naresh Talwar , Jyoti Missra , Kiran Shankar Lagu
发明人： Jack Aurora , Naresh Talwar , Jyoti Missra , Kiran Shankar Lagu
IPC分类号： A61K31/4184
CPC分类号： A61K31/4184 , A61K9/2054 , A61K9/2077
摘要： A pharmaceutical composition comprising i) an intra-granular fraction containing a pharmaceutically acceptable active component and a first excipient and ii) an extra-granular fraction containing a second excipient. The pharmaceutical composition is characterized by being substantially surfactant-free and by exhibiting a rapid-dissolution profile.
摘要翻译：一种药物组合物，其包含i）含有药学上可接受的活性成分和第一赋形剂的颗粒内部分，和ii）含有第二赋形剂的颗粒外级分。药物组合物的特征在于基本上不含表面活性剂并且通过显示快速溶出曲线。

8. 发明授权

US06261601B1 Orally administered controlled drug delivery system providing temporal and spatial control 失效
标题翻译：口服给药控制药物输送系统提供时间和空间控制
公开(公告)号：US06261601B1
公开(公告)日：2001-07-17
申请号：US09152932
申请日：1998-09-14
申请人： Naresh Talwar , Himadri Sen , John N. Staniforth
发明人： Naresh Talwar , Himadri Sen , John N. Staniforth
IPC分类号： A61K946
CPC分类号： A61K9/0065 , A61K31/496
摘要： A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients, the formulation being in the form of a coated or uncoated tablet or capsule.
摘要翻译：片剂或胶囊形式的药物组合物提供药物递送到患者的时间和空间控制的组合以获得有效的治疗结果。药物组合物包含药物，气体发生组分，溶胀剂，粘稠剂和任选的凝胶形成聚合物。溶胀剂属于称为超级崩解剂的一类化合物（例如交联聚乙烯吡咯烷酮或羧甲基纤维素钠）。最初的粘稠溶剂和凝胶形成聚合物之后形成一种水合凝胶基质，其夹带气体，导致片剂或胶囊保留在胃或小肠上部（空间对照）中。同时，水合凝胶基质为药物产生曲折的扩散途径，导致药物的持续释放（时间控制）。优选的每日一次环丙沙星制剂包含69.9％环丙沙星碱，0.34％藻酸钠，1.03％黄原胶，13.7％碳酸氢钠，12.1％交联聚乙烯吡咯烷酮和任选的其它药物赋形剂，该制剂呈涂层或未包衣的片剂或胶囊。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式